Advanced Filters
noise

Liver Disease Clinical Trials

A listing of Liver Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,492 clinical trials
Y Yoon Jun Kim, MD, PhD

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma

19 years of age All Phase 1/2
C Changzhen Shang, MD

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.

18 - 75 years of age All Phase N/A
W Watcharasak Chotiyaputta, Asso Prof

Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis

The hepatitis A virus (HAV) is a significant global public health concern. The hepatitis A virus is transmitted primarily by the faecal-oral route, leading to acute hepatitis. Symptoms include low-grade fever, anorexia, jaundice, and typically resolve without complications. However, HAV infection in patients with chronic liver disease, especially those over …

18 - 70 years of age All Phase 4
J Jinbo Yue, doctor

Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC

This multicenter, prospective, randomized, controlled, open-label, two-arm Phase III clinical trial is designed to evaluate whether adding radiotherapy to oligoprogressive lesions while continuing first-line systemic therapy at the time of oligoprogression can effectively prolong progression-free survival compared to early switching to second-line systemic therapy in oligoprogressive hepatocellular carcinoma.

18 - 75 years of age All Phase 3
D Dalia E Tawfik

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

We will give an anticoagulant against portal vein thrombosis, and watch for the results.

18 - 70 years of age All Phase 4
L Lynn Feun, MD

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.

18 years of age All Phase 2
M Ming-Chih Hou, MD

Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC

The goal of this clinical trial is to evaluate whether endoscopic variceal ligation (EVL) or carvedilol is more effective at preventing the first esophageal variceal bleeding (EVB) in patients with hepatocellular carcinoma (HCC). It will also learn about the safety of EVL and carvedilol in patients with HCC. The main …

20 - 90 years of age All Phase 4
B Bo Chen

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

This study is an open-label, randomized controlled, multicenter, phase III clinical trial

18 - 80 years of age All Phase 3
M Mustafa Azizoğlu

Stem Cell Applications in Biliary Atresia Patients

Recently, mesenchymal stem cell (MSC) transplantation has emerged as a promising treatment for liver cirrhosis in adults. Additionally, bone marrow-derived stem cell transplantation has shown success in treating children with biliary atresia (BA). This study aims to evaluate the efficacy of Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSC) therapy in BA …

2 - 18 years of age All Phase N/A
F Feng Duan, MD

TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension, then the second is the tumor-caused death. It is vital to prevent the portal hypertension by PVTT.

18 - 75 years of age All Phase N/A

Simplify language using AI